Autologous anti-CD19-transduced CD3+ cells (Tecartus®) is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||03/03/2021|
|Rapid review completed||22/03/2021|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of autologous anti-CD19-transduced CD3+ cells compared with the current standard of care|